Exelon Patch delivers rivastigmine through the skin once daily, increasing acetylcholine to support brain signaling. It may modestly improve symptoms, but it does not change the underlying dementia process, according to the DailyMed/FDA prescribing label. Acetylcholine is a chemical messenger used in cholinergic signaling. Rivastigmine temporarily blocks cholinesterase, the enzyme that breaks it down, so more acetylcholine remains available.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who is Exelon Patch for?
- How much benefit should families expect?
- Why does the dose increase slowly?
- Which side effects need monitoring?
- How can caregivers prevent patch errors?
Who is Exelon Patch for?
exelon Patch is not approved for dementia generally. The DailyMed/FDA label specifies dementia of the Alzheimer's type at mild, moderate, or severe stages and mild-to-moderate Parkinson's disease dementia.
That distinction matters because dementia has different causes. A dementia diagnosis alone does not establish that rivastigmine is appropriate; the prescriber must consider the diagnosed type and stage.
How much benefit should families expect?
Across seven placebo-controlled Alzheimer's trials, oral rivastigmine or the 9.5-mg/day patch produced statistically better cognition, daily function, and overall clinical outcomes after six months. However, the Cochrane evidence review characterized the cognitive and functional effects as small. In the pivotal 24-week patch study, 1,195 people with mild-to-moderate Alzheimer's participated.
The 9.5-mg/24-hour patch improved scores on the ADAS-Cog cognitive scale by 1.8 points compared with placebo. These group averages cannot predict one person's response. Families can make follow-up visits more useful by recording changes in specific tasks, communication, and daily functioning rather than expecting a dramatic recovery.
Why does the dose increase slowly?
Treatment starts at 4.6 mg/24 hours. Clinicians increase the dose only after the person has tolerated that strength for at least four weeks. For severe Alzheimer's disease, a 24-week trial found that the 13.3-mg/24-hour patch performed better than the 4.6-mg/24-hour patch on cognition and activities of daily living.
The higher strength is therefore the labeled effective dose for severe disease. An interruption longer than three days changes the plan. Treatment must restart at 4.6 mg/24 hours and be increased gradually again, rather than resuming the previous strength immediately.
Which side effects need monitoring?
Rivastigmine can cause nausea, vomiting, diarrhea, decreased appetite, and weight loss. These effects can increase with the dose.
In one 24-week study cited in the DailyMed/FDA label, 8% of people using the 9.5-mg patch lost at least 7% of their body weight, compared with 6% receiving placebo. A caregiver can help by watching for changes after treatment begins or the dose increases:.
- Record repeated nausea, vomiting, or diarrhea.
- Notice a sustained decrease in appetite or food intake.
- Track weight consistently enough to identify a downward pattern.
- Report persistent or concerning changes to the prescribing clinician.
How can caregivers prevent patch errors?
The old patch must be removed before a new one is applied, and the person should wear only one patch at a time. Accidental use of multiple patches has caused serious reactions, hospitalization, and, rarely, death. A simple daily routine reduces the risk: Before every application, physically confirm that the previous patch is gone and that only one new patch will remain.
- Check the person's skin for yesterday's patch.
- Remove the old patch before opening the new one.
- Apply only the prescribed patch once daily.
- Record the application so another caregiver does not add a second patch.
